Markets:

Overview

News

Currencies

International

Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 Next >

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗

October 15, 2021

Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.

Via Talk Markets

Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗

October 12, 2021

Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.

Via Talk Markets

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program ↗

October 11, 2021

The Week In Psychedelics

Via Benzinga

Former Tilray CEO Joins Psychedelics Company ↗

October 07, 2021

More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ:

Via Benzinga

Topics Cannabis

MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression ↗

October 05, 2021

Psychedelic–focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) disclosed on Tuesday that it has agreed to partner with Sphere Health to...

Via Benzinga

Cannabis Movers & Shakers: Leafly Holdings, Linneo Health, Flowhub, MindMed ↗

October 04, 2021

Leafly Holdings Taps Suresh Krishnaswamy As New CFO The cannabis information platform Leafly Holdings, Inc. recently disclosed ...

Via Benzinga

Topics Cannabis

Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation ↗

October 04, 2021

This article by Gaurav Dubey was originally published on

Via Benzinga

Topics Intellectual Property

COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All ↗

October 04, 2021

Image by Shameer Pk from Pixabay From 25-minute COVID-19 lab tests to psychedelic medicine that is poised to address mental health conditions like PTSD, XPhyto Therapeutics (...

Via Benzinga

6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments? ↗

October 01, 2021

This article by Jason Najum was originally published on

Via Benzinga

Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference ↗

September 30, 2021

The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ...

Via Benzinga

Digital Therapeutics And The Future Of Psychedelic Medicine ↗

September 29, 2021

Digital health and therapeutics will play a crucial role in the future of medicine. Across medical and mental health industries, companies are real...

Via Benzinga

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study ↗

September 27, 2021

The Week In Psychedelics:

Via Benzinga

Which Psychedelic Stock ETF Is Right For You? ↗

September 18, 2021

This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.

Via Talk Markets

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0 ↗

September 15, 2021

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS...

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A ↗

September 07, 2021

Contents

Via Benzinga

Psychedelic Drug Industry Report Card For 2021 ↗

September 01, 2021

In assessing the psychedelic drug industry, a primary focus for investors is drug development.

Via Talk Markets

EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation ↗

August 31, 2021

A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr...

Via Benzinga

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold ↗

August 30, 2021

Contents

Via Benzinga

Magic Mushroom Drug Stock Performances YTD ↗

August 29, 2021

Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”.

Via Talk Markets

MindMed Teams Up With Forian To Improve Real-World Evidence Data To Help Psychiatric Patients ↗

August 24, 2021

Psychedelics-focused medicines company Mind Medicine Inc. (NASDAQ:

Via Benzinga

Cramer Weighs In On RealReal, Affirm Holdings And More ↗

August 17, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said no to RealReal Inc (NASDAQ: REAL). He is not a buyer because there are too many of these guys. Mind Medicine (...

Via Benzinga

Push the Boundaries of DMT Therapy with Mind Medicine ↗

August 16, 2021

Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.

Via InvestorPlace

Topics Cannabis

MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline ↗

August 16, 2021

The psychedelics-focused medicines company MindMed (NASDAQ:

Via Benzinga

No Matter How the Pandemic Rolls, Mind Medicine Will Prevail ↗

August 11, 2021

While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling.

Via InvestorPlace

Which Psychedelic Drug Has The Most Commercial Potential? ↗

August 10, 2021

As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 ↗

August 05, 2021

Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:

Via Benzinga

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected ↗

August 02, 2021

Last week in Psychedelics:

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

Starting at $3.75/week.

Subscribe Today